Literature DB >> 18453721

Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, an antibody specific for the Abeta peptides associated with Alzheimer's disease.

Kwok S Wun1, Luke A Miles, Gabriela A N Crespi, Kaye Wycherley, David B Ascher, Kevin J Barnham, Roberto Cappai, Konrad Beyreuther, Colin L Masters, Michael W Parker, William J McKinstry.   

Abstract

The murine monoclonal antibody WO2 specifically binds the N-terminal region of the amyloid beta peptide (Abeta) associated with Alzheimer's disease. This region of Abeta has been shown to be the immunodominant B-cell epitope of the peptide and hence is considered to be a basis for the development of immunotherapeutic strategies against this prevalent cause of dementia. Structural studies have been undertaken in order to characterize the molecular basis for antibody recognition of this important epitope. Here, details of the crystallization and X-ray analysis of the Fab fragment of the unliganded WO2 antibody in two crystal forms and of the complexes that it forms with the truncated Abeta peptides Abeta(1-16) and Abeta(1-28) are presented. These crystals were all obtained using the hanging-drop vapour-diffusion method at 295 K. Crystals of WO2 Fab were grown in polyethylene glycol solutions containing ZnSO(4); they belonged to the orthorhombic space group P2(1)2(1)2(1) and diffracted to 1.6 A resolution. The complexes of WO2 Fab with either Abeta(1-16) or Abeta(1-28) were cocrystallized from polyethylene glycol solutions. These two complex crystals grew in the same space group, P2(1)2(1)2(1), and diffracted to 1.6 A resolution. A second crystal form of WO2 Fab was grown in the presence of the sparingly soluble Abeta(1-42) in PEG 550 MME. This second form belonged to space group P2(1) and diffracted to 1.9 A resolution.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18453721      PMCID: PMC2376392          DOI: 10.1107/S1744309108011718

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  13 in total

Review 1.  Alzheimer's disease is a synaptic failure.

Authors:  Dennis J Selkoe
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

2.  The CCP4 suite: programs for protein crystallography.

Authors: 
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1994-09-01

3.  Screening and optimization strategies for macromolecular crystal growth.

Authors:  R Cudney; S Patel; K Weisgraber; Y Newhouse; A McPherson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1994-07-01

4.  Solution structure of amyloid beta-peptide (25-35) in different media.

Authors:  Anna M D'Ursi; Maria R Armenante; Remo Guerrini; Severo Salvadori; Giuseppe Sorrentino; Delia Picone
Journal:  J Med Chem       Date:  2004-08-12       Impact factor: 7.446

Review 5.  Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease.

Authors:  T Hamaguchi; K Ono; M Yamada
Journal:  Cell Mol Life Sci       Date:  2006-07       Impact factor: 9.261

6.  Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis.

Authors:  C S Atwood; R D Moir; X Huang; R C Scarpa; N M Bacarra; D M Romano; M A Hartshorn; R E Tanzi; A I Bush
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

7.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor.

Authors:  J Kang; H G Lemaire; A Unterbeck; J M Salbaum; C L Masters; K H Grzeschik; G Multhaup; K Beyreuther; B Müller-Hill
Journal:  Nature       Date:  1987 Feb 19-25       Impact factor: 49.962

8.  Solution structures in aqueous SDS micelles of two amyloid beta peptides of A beta(1-28) mutated at the alpha-secretase cleavage site (K16E, K16F).

Authors:  S A Poulsen; A A Watson; D P Fairlie; D J Craik
Journal:  J Struct Biol       Date:  2000-06       Impact factor: 2.867

9.  Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay.

Authors:  N Ida; T Hartmann; J Pantel; J Schröder; R Zerfass; H Förstl; R Sandbrink; C L Masters; K Beyreuther
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

Review 10.  The molecular link between beta- and gamma-secretase activity on the amyloid beta precursor protein.

Authors:  M Tabaton; E Tamagno
Journal:  Cell Mol Life Sci       Date:  2007-09       Impact factor: 9.261

View more
  7 in total

1.  Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β.

Authors:  Gabriela A N Crespi; David B Ascher; Michael W Parker; Luke A Miles
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-02-20       Impact factor: 1.056

2.  Theory for the Liquid-Liquid Phase Separation in Aqueous Antibody Solutions.

Authors:  Miha Kastelic; Vojko Vlachy
Journal:  J Phys Chem B       Date:  2018-01-27       Impact factor: 2.991

3.  Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.

Authors:  Luke A Miles; Gabriela A N Crespi; Larissa Doughty; Michael W Parker
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

4.  Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.

Authors:  Gabriela A N Crespi; Stefan J Hermans; Michael W Parker; Luke A Miles
Journal:  Sci Rep       Date:  2015-04-16       Impact factor: 4.379

5.  Deletion of the type-1 interferon receptor in APPSWE/PS1ΔE9 mice preserves cognitive function and alters glial phenotype.

Authors:  Myles R Minter; Zachery Moore; Moses Zhang; Kate M Brody; Nigel C Jones; Sandy R Shultz; Juliet M Taylor; Peter J Crack
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

6.  mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures.

Authors:  Douglas E V Pires; David B Ascher
Journal:  Nucleic Acids Res       Date:  2016-05-23       Impact factor: 16.971

7.  Abrogation of type-I interferon signalling alters the microglial response to Aβ1-42.

Authors:  Zachery Moore; Frank Mobilio; Frederick R Walker; Juliet M Taylor; Peter J Crack
Journal:  Sci Rep       Date:  2020-02-21       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.